Which has preferable valuation and earnings, TARA or FLNA?

Protara Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is TARA or FLNA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Cassava Sciences N/A -53.90% -34.20%

Cassava Sciences (FLNA) Competitors

$1.23 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Protara Therapeutics (TARA), Avidity Biosciences (RNA), Coherus Oncology (CHRS), Karyopharm Therapeutics (KPTI), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Protara Therapeutics' return on equity of -38.70% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Cassava Sciences	N/A	-53.90%	-34.20%

Protara Therapeutics presently has a consensus price target of $26.25, indicating a potential upside of 546.55%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 306.50%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Protara Therapeutics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Protara Therapeutics and 0 mentions for Cassava Sciences. Protara Therapeutics' average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Cassava Sciences	Neutral

Protara Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Protara Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Summary

Protara Therapeutics beats Cassava Sciences on 10 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Avidity Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Cassava Sciences	N/A	-53.90%	-34.20%

In the previous week, Avidity Biosciences' average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Avidity Biosciences	Neutral
Cassava Sciences	Neutral

Cassava Sciences has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	6.37	-$322.30M	-$0.97	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

38.1% of Cassava Sciences shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avidity Biosciences currently has a consensus target price of $66.81, suggesting a potential upside of 389.47%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 306.50%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Avidity Biosciences beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Cassava Sciences	N/A	-53.90%	-34.20%

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
Cassava Sciences	Neutral

Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.30	$168.02M	$1.67	0.87
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

Coherus Oncology currently has a consensus target price of $8.67, indicating a potential upside of 497.70%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 306.50%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Coherus Oncology is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Coherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Karyopharm Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for Karyopharm Therapeutics and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Karyopharm Therapeutics	Neutral

Cassava Sciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Karyopharm Therapeutics	$151.12M	1.44	-$196.04M	-$15.09	N/A

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 306.50%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 78.82%. Given Cassava Sciences' higher probable upside, research analysts clearly believe Cassava Sciences is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Cassava Sciences on 9 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Cassava Sciences has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$36.49M	6.26	-$119.72M	-$1.97	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Cassava Sciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Cassava Sciences' return on equity of -53.90% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Cassava Sciences	N/A	-53.90%	-34.20%

In the previous week, Voyager Therapeutics had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for Cassava Sciences. Voyager Therapeutics' average media sentiment score of 0.45 beat Cassava Sciences' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
Cassava Sciences	Neutral

Voyager Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 336.51%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 306.50%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Voyager Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Voyager Therapeutics beats Cassava Sciences on 10 of the 16 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.42M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.76	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.37	99.46
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.80	4.32	10.96	6.46
Net Income	-$90.97M	$64.45M	$3.57B	$337.01M
7 Day Performance	2.50%	2.97%	2.12%	1.69%
1 Month Performance	-6.82%	6.83%	5.25%	3.81%
1 Year Performance	-38.81%	29.07%	33.29%	23.90%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
FLNA Cassava Sciences	1.5774 of 5 stars	$1.23 flat	$5.00 +306.5%	-38.8%	$59.42M	N/A	N/A	20
TARA Protara Therapeutics	3.0931 of 5 stars	$4.09 -0.8%	$26.25 +542.6%	+39.7%	$229.58M	N/A	N/A	30
RNA Avidity Biosciences	1.9465 of 5 stars	$13.29 +0.8%	$66.81 +402.7%	-53.1%	$227.34M	$36.68M	N/A	190
CHRS Coherus Oncology	3.0467 of 5 stars	$1.46 -3.0%	$8.67 +495.6%	+81.0%	$225.98M	$42.17M	0.88	330
KPTI Karyopharm Therapeutics	1.5539 of 5 stars	$9.80 -4.1%	$17.17 +75.3%	+107.8%	$222.23M	$151.12M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

How does Cassava Sciences compare to Protara Therapeutics?

Summary

How does Cassava Sciences compare to Avidity Biosciences?

Summary

How does Cassava Sciences compare to Coherus Oncology?

Summary

How does Cassava Sciences compare to Karyopharm Therapeutics?

Summary

How does Cassava Sciences compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

How does Cassava Sciences compare to Protara Therapeutics?

Is TARA or FLNA more profitable?

Do analysts rate TARA or FLNA?

Does the media refer more to TARA or FLNA?

Which has more volatility & risk, TARA or FLNA?

Do institutionals and insiders believe in TARA or FLNA?

Which has preferable valuation and earnings, TARA or FLNA?

Summary

How does Cassava Sciences compare to Avidity Biosciences?

Which has more volatility and risk, RNA or FLNA?

Is RNA or FLNA more profitable?

Does the media prefer RNA or FLNA?

Which has better valuation and earnings, RNA or FLNA?

Do institutionals & insiders have more ownership in RNA or FLNA?

Do analysts rate RNA or FLNA?

Summary

How does Cassava Sciences compare to Coherus Oncology?

Is CHRS or FLNA more profitable?

Does the media refer more to CHRS or FLNA?

Which has higher earnings & valuation, CHRS or FLNA?

Do insiders and institutionals believe in CHRS or FLNA?

Which has more volatility and risk, CHRS or FLNA?

Do analysts prefer CHRS or FLNA?

Summary

How does Cassava Sciences compare to Karyopharm Therapeutics?

Which has more volatility and risk, FLNA or KPTI?

Is FLNA or KPTI more profitable?

Does the media prefer FLNA or KPTI?

Which has stronger earnings & valuation, FLNA or KPTI?

Do analysts recommend FLNA or KPTI?

Do institutionals & insiders believe in FLNA or KPTI?

Summary

How does Cassava Sciences compare to Voyager Therapeutics?

Which has stronger valuation and earnings, VYGR or FLNA?

Is VYGR or FLNA more profitable?

Does the media refer more to VYGR or FLNA?

Which has more volatility & risk, VYGR or FLNA?

Do analysts recommend VYGR or FLNA?

Do insiders and institutionals have more ownership in VYGR or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools